APYX

APYX MEDICAL CORP

Healthcare | Micro Cap

-$0.07

EPS Forecast

$13.9

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

APYX Q3 2026 Earnings: AYON Growth Lifts Revenue Outlook as Costs Narrow the Gap

Tick­er: APYX • EPS discussions emerge as a topic for the quarter, though per-share figures aren’t provided in the release. The press release emphasizes revenue forecast discipline and Adjusted EBITDA trends rather than a traditional earnings per share number.

Apyx Medical Corporation (APYX) posted corresponding figures for the third quarter of 2026 that underscore a pivot in its business mix toward Surgical Aesthetics, paired with a measured improvement in profitability metrics. The company reported total revenue of $14.0 million for the quarter ended September 30, 2026, up from $12.9 million in the same period a year earlier. The growth is anchored by the Surgical Aesthetics segment, which generated $13.0 million in the quarter, up from $11.1 million in Q3 2025.

GAAP net loss attributable to stockholders narrowed to $1.8 million in Q3 2026 from $2.0 million in Q3 2025, while Adjusted EBITDA shifted to a positive $0.4 million for the quarter (versus a loss of $0.1 million in the prior year). All told, the trajectory points to tighter operating discipline even as the company remains in the investment phase for growth initiatives.

Driving the mix: AYON growth and the OEM headwind

The quarterly revenue mix highlights a durable strength in Surgical Aesthetics, where revenue climbed to $13.0 million in Q3 2026, supported by domestic sales and international Renuvion generator deployments. The year-over-year acceleration here is notable, especially against a backdrop of other components of the business.

OEM revenue was approximately $1.1 million in the quarter, but the year-over-year comparison shows a roughly 42% decline. That divergence underscores the ongoing challenge of diversification within the company’s revenue base and the sensitivity of some channels to broader market dynamics and customer deployment cycles.

Product momentum: reusable power liposuction handpiece launch

In a notable operational milestone, APYX initiated the full commercial launch of the reusable power liposuction handpiece for the AYON Body Contouring System in Q3 2026, following positive feedback from key early adopter surgeons. The launch supports the company’s thesis that AYON can broaden its addressable market beyond traditional offerings and potentially improve long-term installed base and service revenue dynamics.

Guidance remains intact: a revenue forecast that matters

APYX affirmed its revenue forecast for fiscal year 2026 of $59.0 million to $60.0 million. Keeping guidance steady in the face of a mixed-margin environment signals management’s confidence in Surgical Aesthetics momentum and in ongoing demand for AYON, even as OEM contributions prove uneven. The guidance frame gives investors a compass for EPS trajectory expectations, even though an explicit EPS consensus figure and quarterly earnings surprise metric aren’t published in the press release.

Financial narrative: what this portends for APYX and peers

The quarterly results reflect a narrative familiar to medical devices companies riding a dual track of product launches and channel optimization. The positive delta in Adjusted EBITDA suggests the company is moving closer to cash-flow balance as it scales Surgical Aesthetics and commercializes AYON components. Yet the year-over-year decline in OEM revenue highlights ongoing sensitivity to end-market mix and international vs. domestic deployment cycles—an area where peers in surgical aesthetics and energy-based devices often see similar volatility.

For APYX, the key near-term questions include: Can the AYON-driven revenue cadence accelerate enough to lift Adjusted EBITDA beyond the current quarter? Will the OEM segment stabilize as licensing and cooperation agreements mature, or will it continue to drag on the overall margin profile? And will the company’s EPS trajectory align with EPS consensus expectations as management provides more frequent updates on operating leverage? While the press release does not present per-share metrics, the direction on profitability and the confirmed revenue path gives a plausible runway for investors who track earnings quality and revenue realism.

Strategy in a sector context: peers, competition, and the regulatory rhythm

Within the broader surgical aesthetics space, a company like APYX sits at a juncture where product innovation, adoption speed, and international expansion determine the pace of top-line growth. The AYON launch could be a differentiator if it materially broadens addressable markets and improves physician adoption rates. Sector peers will watch not only the absolute revenue prints but the cadence of gross margin, operating expense discipline, and the sustainability of Adjusted EBITDA gains as the company scales. In a world where healthcare tech cycles can be patient-by-patient, the speed at which APYX converts early adopter feedback into repeat orders will be a telling signal for the durability of its revenue forecast and for the stability of its earnings storyline.

Bottom line

APYX’s Q3 2026 results show a constructive move toward revenue growth and profitability after a period of investment-heavy execution. The continued focus on AYON and the expanded use of Renuvion generators suggests the company remains tethered to a growth thesis that could, if sustained, translate into a steadier earnings narrative for investors who care about per-share outcomes as well as the top line. For now, the stock’s journey will likely hinge on the next set of quarterly prints and the degree to which management can translate the AYON momentum into tangible, longer-term earnings power.

Conference call: Today at 8:00 a.m. ET. For investors, the press release’s revenue forecast and profitability metrics will remain the focal point as market participants weigh APYX against its EPS trajectory and earnings surprise expectations across the sector.